Development and clinical application of treatment for seasonal allergic rhinitis symptom caused by salivary secretory type IgA production.
- Conditions
- Seasonal allergic rhinitis
- Registration Number
- JPRN-UMIN000026428
- Lead Sponsor
- Department of Oral Integrated Medicine Kanagawa Dental University
- Brief Summary
The symptoms of allergic rhinitis severity classification (from 0 to12 points) before and after mouthpiece attachment were significantly improved after the experimental group (before 9.7) (after 4.3), whereas the control group The salivary flow rate was measured as salivary secretion rate (micro g / min), and it was measured after the experimental group (0.6) before loading (after 1.0 +0.6), but the control group did not change (before 0.7) , (after 1.0)). As a result of multiple item saliva test, the mouthpiece of the experimental group An increase in acid buffering capacity was observed before and after mounting. As a result of measuring the salivary IgA concentration (micro g /ml), the experimental group (10.4) before the mouthpiece was attached was significantly reduced compared to the control group (19.2). The salivary IgA concentration after wearing the mouthpiece did not change in both the experimental group and the control group, but the salivary IgA secretion rate (micro g/ min) in the experimental group. Results: Rhinitis severity classification before and after NG was significantly improved before and after NG. As a result of measuring the saliva flow rate, it was significantly increased before and after NG. It was revealed that salivary IgA secretion concentration was significantly decreased in hay fever patients. Conclusion: NG used for dental care showed the possibility of alleviating symptoms of allergic rhinitis caused with pollinosis by increasing saliva amount and salivary IgA secretion rate.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Not provided
1) Those who are undergoing treatment due to infection with hemophilia, hepatitis, HIV, etc, and who are at risk of treatment due to high blood pressure, diabetes etc. 2) Pregnant women or lactating women 3) Person who has participated in the trial within 12 weeks before the start of this procedure 4) Person who judged that the dental clinic in charge is not appropriate for other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluate relief of allergic rhinitis symptoms before and after mouthpiece attachment by allergic rhinitis severity classification.
- Secondary Outcome Measures
Name Time Method Furthermore, changes in salivary secretion rate, salivary IgA concentration, salivary IL-33 concentration, and saliva properties are evaluated.